Does TILDRAKIZUMAB Cause Prostate cancer? 14 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Prostate cancer have been filed in association with TILDRAKIZUMAB (ILUMYA). This represents 1.6% of all adverse event reports for TILDRAKIZUMAB.
14
Reports of Prostate cancer with TILDRAKIZUMAB
1.6%
of all TILDRAKIZUMAB reports
0
Deaths
3
Hospitalizations
How Dangerous Is Prostate cancer From TILDRAKIZUMAB?
Of the 14 reports, 3 (21.4%) required hospitalization, and 1 (7.1%) were considered life-threatening.
Is Prostate cancer Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TILDRAKIZUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does TILDRAKIZUMAB Cause?
Product dose omission issue (53)
Death (50)
Drug ineffective (50)
Psoriasis (37)
Urinary tract infection (36)
Pneumonia (33)
Off label use (27)
Condition aggravated (25)
Covid-19 (25)
Inappropriate schedule of product administration (22)
What Other Drugs Cause Prostate cancer?
RANITIDINE (60,641)
LEUPROLIDE (1,736)
ABIRATERONE (661)
ENZALUTAMIDE (642)
ADALIMUMAB (573)
ETANERCEPT (482)
METHOTREXATE (444)
INFLIXIMAB (376)
LENALIDOMIDE (366)
PREDNISONE (317)
Which TILDRAKIZUMAB Alternatives Have Lower Prostate cancer Risk?
TILDRAKIZUMAB vs TILDRAKIZUMAB-ASMN
TILDRAKIZUMAB vs TILIDINE
TILDRAKIZUMAB vs TIMOLOL
TILDRAKIZUMAB vs TIMOLOL\TRAVOPROST
TILDRAKIZUMAB vs TINIDAZOLE